Potential Effect of Dialyzer Leaching of BPA From the Fresenius Optiflux 160NR Compared to the Nipro ELISIO-15H

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-30

Study Completion Date

2016-07-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to identify hepatic enzyme and estrogen-dependent biochemical changes that occur when dialysis patients are treated with dialyzers known to leach BPA (Bisphenol-A) into the blood, such as the commercially available Fresenius F160NR, as compared with the same chemical evaluations in patients being treated with the non BPA containing Nipro Elisio-15H dialyzer. Evaluations of patient's chemistries will be obtained prior to and after 2 months of standard dialysis treatments with each dialyzer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Exposure Of Bisphenol Analogues In Chronic Kidney Disease and Dialysis Patients

NCT04100421

Chronic Kidney Diseases Hemodialysis Complication

COMPLETED

A Clinical Study Comparing Basic Performance and Hemocompatibility of 3 Different Dialyzers in Hemodialysis Patients

NCT02433210

End Stage Renal Disease (ESRD)

COMPLETED NA

The Impact of Delflex on Mesothelial Cell Viability and Peritoneal Transport

NCT01292863

End Stage Renal Disease

WITHDRAWN NA

Comparison of Hemodialysis With Medium Cut-off Dialyzer (Theranova) and High Flux Dialyzer

NCT03211676

End Stage Renal Disease Dialysis Related Complication Dialysis Amyloidosis

COMPLETED NA

Biomonitoring of Internal Exposure to MNPLs, and Its Effects, in Blood of Patients With Chronic Kidney Disease (CKD)

NCT05155267

Chronic Kidney Diseases Microplastics Nanoplastics +1 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators propose to elucidate any eventual biochemical changes, and in particular, the in vivo estrogenic activity of BPA (Bisphenol-A), when BPA is being leached into the circulation by the Fresenius 160NR dialyzer as opposed to the same biochemical changes when there is no BPA being leached, as with the non-BPA containing Nipro Elisio-15H dialyzer. The estrogen dependent biochemical end points in humans include free testosterone, sex hormone binding globulin (SHBG) and thyroid binding globulin (TBG).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End Stage Renal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dialyzer Comparison

2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR followed by 2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H

Group Type EXPERIMENTAL

FRESENIUS 160NR

Intervention Type DEVICE

2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR DIALYZER

NIPRO ELISIO-15H

Intervention Type DEVICE

2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H DIALYZER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FRESENIUS 160NR

2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR DIALYZER

Intervention Type DEVICE

NIPRO ELISIO-15H

2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H DIALYZER

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male ESRD patients 18 years or older
* Stable on hemodialysis for more than 3 months
* Stable hematocrit equal to or above 29 %
* Stable vascular access
* Stable anticoagulation
* No active infection
* Able to sign informed consent and able to participate in the study
* Medically stable

Exclusion Criteria

* Participation in another study which may interfere with the planned study
* Active infection
* Medical conditions which may interfere with the study (unstable cardiac status, chronic liver disease, active hepatitis as defined by elevated liver enzymes)
* Females (It is expected that potential changes in estrogenic activity that might be seen in patients exposed to BPA will be modest and would be masked by naturally occurring variability of estrogen activity in women at varying stages of gonadal activity (pre, post-menopausal, different points in menstrual cycle, eventual pregnancy, etc). Thus, limiting study to adult males will maximize the possibility of detecting any changes in estrogenic activity.)

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No